Makvandi M, Dupis E, Engle JW, Nortier FM, Fassbender ME, Simon S, et al. Alpha-Emitters and targeted alpha therapy in oncology: from basic science to clinical investigations. Target Oncol. 2018;13:189–203. https://doi.org/10.1007/s11523-018-0550-9.

Article  PubMed  Google Scholar 

Sathekge M, Morgenstern A. Advances in targeted alpha therapy of cancer. Eur J Nucl Med Mol Imaging. 2024;51:1205–6. https://doi.org/10.1007/s00259-024-06658-1.

Article  PubMed  Google Scholar 

Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS. α-Emitters for radiotherapy: from basic radiochemistry to clinical Studies-Part 1. J Nucl Med. 2018;59:878–84. https://doi.org/10.2967/jnumed.116.186338.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kratochwil C, Haberkorn U, Giesel FL. 225Ac-PSMA-617 for therapy of prostate Cancer. Semin Nucl Med. 2020;50:133–40. https://doi.org/10.1053/j.semnuclmed.2020.02.004.

Article  PubMed  Google Scholar 

Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23. https://doi.org/10.1056/NEJMoa1213755.

Article  CAS  PubMed  Google Scholar 

Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. An overview of targeted alpha therapy with 225Actinium and 213Bismuth. Curr Radiopharm. 2018;11:200–8. https://doi.org/10.2174/1874471011666180502104524.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted α-Therapy of metastatic Castration-Resistant prostate Cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624–31. https://doi.org/10.2967/jnumed.117.191395.

Article  CAS  PubMed  Google Scholar 

Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, et al. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:824–45. https://doi.org/10.1007/s00259-017-3900-4.

Article  CAS  PubMed  Google Scholar 

Hindorf C, Chittenden S, Aksnes A-K, Parker C, Flux GD. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl Med Commun. 2012;33:726–32. https://doi.org/10.1097/MNM.0b013e328353bb6e.

Article  CAS  PubMed  Google Scholar 

Pacilio M, Ventroni G, de Vincentis G, Cassano B, Pellegrini R, Di Castro E, et al. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride. Eur J Nucl Med Mol Imaging. 2016;43:21–33. https://doi.org/10.1007/s00259-015-3150-2.

Article  CAS  PubMed  Google Scholar 

Ocak M, Toklu T, Demirci E, Selçuk N, Kabasakal L. Post-therapy imaging of 225Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor. Eur J Nucl Med Mol Imaging. 2020;47:2711–2. https://doi.org/10.1007/s00259-020-04725-x.

Article  PubMed  Google Scholar 

Gosewisch A, Schleske M, Gildehaus FJ, Berg I, Kaiser L, Brosch J, et al. Image-based dosimetry for 225Ac-PSMA-I&T therapy using quantitative SPECT. Eur J Nucl Med Mol Imaging. 2021;48:1260–1. https://doi.org/10.1007/s00259-020-05024-1.

Article  CAS  PubMed  Google Scholar 

Delker A, Schleske M, Liubchenko G, Berg I, Zacherl MJ, Brendel M, et al. Biodistribution and dosimetry for combined 177LuLu-PSMA-I&T/225AcAc-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging. Eur J Nucl Med Mol Imaging. 2023;50:1280–90. https://doi.org/10.1007/s00259-022-06092-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miederer M, Benešová-Schäfer M, Mamat C, Kästner D, Pretze M, Michler E, et al. Alpha-Emitting radionuclides: current status and future perspectives. Pharmaceuticals (Basel). 2024. https://doi.org/10.3390/ph17010076.

Article  PubMed  Google Scholar 

Nelson BJB, Wilson J, Andersson JD, Wuest F. Theranostic imaging surrogates for targeted alpha therapy: progress in production, purification, and applications. Pharmaceuticals (Basel). 2023. https://doi.org/10.3390/ph16111622.

Article  PubMed  PubMed Central  Google Scholar 

Morgan KA, Rudd SE, Noor A, Donnelly PS. Theranostic nuclear medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 radionuclides. Chem Rev. 2023;123:12004–35. https://doi.org/10.1021/acs.chemrev.3c00456.

Article  CAS  PubMed  Google Scholar 

Meredith R, Torgue J, Shen S, Fisher DR, Banaga E, Bunch P, et al. Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab. J Nucl Med. 2014;55:1636–42. https://doi.org/10.2967/jnumed.114.143842.

Article  CAS  PubMed  Google Scholar 

Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, et al. Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm. 2014;29:12–7. https://doi.org/10.1089/cbr.2013.1531.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bauer D, Carter LM, Atmane MI, de Gregorio R, Michel A, Kaminsky S, et al. 212Pb-Pretargeted theranostics for pancreatic Cancer. J Nucl Med. 2023. https://doi.org/10.2967/jnumed.123.266388.

Article  PubMed  PubMed Central  Google Scholar 

Chapeau D, Koustoulidou S, Handula M, Beekman S, de Ridder C, Stuurman D, et al. [212Pb]Pb-eSOMA-01: A promising radioligand for targeted alpha therapy of neuroendocrine tumors. Pharmaceuticals. 2023. https://doi.org/10.3390/ph16070985.

Article  PubMed  PubMed Central  Google Scholar 

Durand-Panteix S, Monteil J, Sage M, Garot A, Clavel M, Saidi A, et al. Preclinical study of 212Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma. Br J Cancer. 2021;125:1657–65. https://doi.org/10.1038/s41416-021-01585-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiao R, Allen KJH, Malo ME, Yilmaz O, Wilson J, Nelson BJB, et al. A theranostic approach to imaging and treating melanoma with 203Pb/212Pb-Labeled antibody targeting melanin. Cancers (Basel). 2023. https://doi.org/10.3390/cancers15153856.

Article  PubMed  PubMed Central  Google Scholar 

Li J, Huang T, Hua J, Wang Q, Su Y, Chen P, et al. CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment. J Exp Clin Cancer Res. 2023;42:61. https://doi.org/10.1186/s13046-023-02636-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li M, Baumhover NJ, Liu D, Cagle BS, Boschetti F, Paulin G, et al. Preclinical evaluation of a lead specific Chelator (PSC) conjugated to radiopeptides for 203Pb and 212Pb-Based theranostics. Pharmaceutics. 2023. https://doi.org/10.3390/pharmaceutics15020414.

Article  PubMed  PubMed Central  Google Scholar 

Lee D, Li M, Liu D, Baumhover NJ, Sagastume EA, Marks BM, et al. Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2023. https://doi.org/10.1007/s00259-023-06494-9.

Article  PubMed  PubMed Central  Google Scholar 

Pretze M, Michler E, Runge R, Wetzig K, Tietze K, Brandt F, et al. Influence of the molar activity of 203/212Pb-PSC-PEG2-TOC on somatostatin receptor type 2-Binding and cell uptake. Pharmaceuticals (Basel). 2023. https://doi.org/10.3390/ph16111605.

Article  PubMed  PubMed Central  Google Scholar 

Delpassand ES, Tworowska I, Esfandiari R, Torgue J, Hurt J, Shafie A, Núñez R. Targeted α-Emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic SSTR-Expressing neuroendocrine tumors: First-in-Humans Dose-Escalation clinical trial. J Nucl Med. 2022;63:1326–33. https://doi.org/10.2967/jnumed.121.263230.

Article  CAS